Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification(AL-005) | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07682792 | Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia(GEMSTONE) | not yet recruiting | Phase 2 | 24 | Washington University School of Medicine |
| 1 |
| Jul 6, 2026 |
| clinicaltrials |
| NCT07684950 | Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy | not yet recruiting | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07682415 | Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0(ZS) | not yet recruiting | Phase 2 | 60 | Yi ShuhuaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 25 | Jennifer WoyachOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677813 | Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 66 | Ou Bai, MD/PHDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07597941 | Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | not yet recruiting | Phase 2 / Phase 3 | 20 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jun 30, 2026 | clinicaltrials |
| NCT07674810 | A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07676175 | A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) | not yet recruiting | Phase 2 | 120 | BeBetter Med IncINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07528417 | Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)(MYELO-CAN:ABX) | not yet recruiting | Phase 2 | 75 | University of ManitobaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07614360 | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM-16) | not yet recruiting | Phase 2 | 150 | GlaxoSmithKlineINDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07664839 | Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations | not yet recruiting | Phase 2 | 148 | Shen yangOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07247097 | ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma(ELDORADO) | not yet recruiting | Phase 2 | 160 | Massachusetts General HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07572929 | A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant(PREeMPT) | not yet recruiting | Phase 2 | 450 | Medical College of WisconsinOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07563010 | Menin-Inhibitor Targeted Maintenance in AML | not yet recruiting | Phase 2 | 146 | Center for International Blood and Marrow Transplant ResearchNETWORK | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07658352 | A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 114 | Shanghai Helioson Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658924 | Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma(BEST-CTCL) | not yet recruiting | Phase 2 | 35 | Peking University First HospitalOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07607925 | A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL | not yet recruiting | Phase 1 / Phase 2 | 49 | GlaxoSmithKlineINDUSTRY | 3 | Jun 18, 2026 | clinicaltrials |
| NCT07643636 | Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML | not yet recruiting | Phase 2 | 46 | Dongguan People's HospitalOTHER_GOV | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07654465 | Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma(ROMA) | not yet recruiting | Phase 2 | 144 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma(BELAMI) | not yet recruiting | Phase 1 / Phase 2 | 44 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647432 | HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV(HEME-25) | not yet recruiting | Phase 2 / Phase 3 | 17 | University of Illinois at ChicagoOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT07641010 | PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07642453 | VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | not yet recruiting | Phase 2 | 110 | Hematology department of the 920th hospitalOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07636486 | Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies | not yet recruiting | Phase 2 / Phase 3 | 90 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment | not yet recruiting | Phase 2 | 90 | SWOG Cancer Research NetworkNETWORK | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07626021 | Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms | not yet recruiting | Phase 2 | 15 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07622784 | Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma | not yet recruiting | Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624799 | Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).(PACIFIC) | not yet recruiting | Phase 2 | 82 | French Innovative Leukemia OrganisationOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07598110 | FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML(FT-RIC-HAPLO) | not yet recruiting | Phase 2 | 77 | Institut Paoli-CalmettesOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma(CONQUISTADOR) | not yet recruiting | Phase 1 / Phase 2 | 220 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07593482 | Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.(FC-BALANCE) | not yet recruiting | Phase 2 | 92 | Swiss Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07585747 | A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide(CUREMZL002) | not yet recruiting | Phase 2 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07517705 | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 50 | University of NebraskaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07582159 | Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 58 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07572175 | Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity(SPARTACUS) | not yet recruiting | Phase 2 | 60 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07573670 | A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia | not yet recruiting | Phase 2 | 52 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07468916 | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | not yet recruiting | Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07567014 | Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS | not yet recruiting | Phase 2 | 60 | NYU Langone HealthOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL(FRONTIER) | not yet recruiting | Phase 2 | 52 | Miltenyi Biomedicine GmbHINDUSTRY | 0 | May 6, 2026 | clinicaltrials |
| NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07554482 | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 34 | Beijing Tongren HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07552649 | Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia(MATCH-Treg) | not yet recruiting | Phase 2 | 28 | Antonio PieriniOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07550855 | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma(FLOURISH) | not yet recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07539779 | Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis | not yet recruiting | Phase 2 / Phase 3 | 196 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 7, 2026source: clinicaltrials